NASDAQ: AEMD · Industrial Applications and Services · 8 alerts · CIK 882291
Share price
$5.01Close, Nov 16
Market cap
$8.05M
Shares outstanding
1.61MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Aethlon Medical Inc filings on SEC EDGAR ↗
Aethlon Medical M&A Deal with North Immunology, Inc.
Aethlon Medical provided a status update on its pending merger with North Immunology, Inc., originally announced on September 17, 2026. The filing includes an updated investor presentation that North Immunology will use in meetings with investors regarding the transaction and a concurrent private placement.
Aethlon Medical reported a net loss of $4.17 million for the six months ended September 30, 2026, compared to $3.25 million in the prior year period, driven largely by increased professional fees. The company is currently pursuing a merger with North Immunology, Inc. and has raised capital through common stock issuances to maintain a cash balance of approximately $6.49 million.
Aethlon Medical reported financial results for its fiscal second quarter ended September 30, 2026, highlighting a cash position of $6.5 million and a 77.2% increase in operating expenses due to merger-related professional fees. The company is currently progressing through a definitive merger agreement with North Immunology, Inc., which includes a contingent value right (CVR) for existing shareholders related to the legacy Hemopurifier business.
“We advanced our clinical program during the quarter. We treated the second participant in the third and final dosing cohort of our Phase 1 oncology study in Australia. We have treated eight patients across the three dosing cohorts to date and continue to pursue enrollment of one additional patient.”